Back to top

Nuvectis Pharma Stock Trades Below CEO Ron Bentsur's Insider Buy Price

Nuvectis Pharma insiders, including CEO Ron Bentsur, recently purchased shares at $18.32–$20.00, with the stock briefly trading 4.8% below the CEO's price. Multiple insider buys signal confidence and serve as key benchmarks for investors amid volatile biotech market conditions..

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Nuvectis Pharma, Inc. (NVCT)